Stock analysis searches answered, part 12 of 43

Irenic acquisition corp. bullish and bearish analyst opinions

This section ties “Irenic acquisition corp. bullish and bearish analyst opinions” to Irenic Acquisition Corp. (ticker IACQ, IACQU, IACQW), SEC Central Index Key 2122505, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-04, and this view starts from filings dated on or before 2026-05-01. Nothing here is a recommendation to trade the security.

Analyst ratings, price targets and “bullish” or “bearish” calls on Irenic Acquisition Corp. (CIK 2122505) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Irenic Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-04-28.

Current reports. Of the 5 8-K or 6-K reports in Irenic Acquisition Corp.’s recent EDGAR index, the 1 listed here run from 2026-04-29 to 2026-04-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 30 recent EDGAR filings, Irenic Acquisition Corp. most often filed 3 (6), 8-K (5), SCHEDULE 13G (3), 4 (2). A selection from 2026-04-27 to 2026-05-04:

The full record for CIK 2122505 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-03-25. One example from this record is the SCHEDULE 13G filed 2026-08-12 (document). Insider trades for Irenic Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lifevantage corporation bullish and bearish analyst opinions

This section ties “Lifevantage corporation bullish and bearish analyst opinions” to Lifevantage Corp (ticker LFVN), SEC Central Index Key 849146, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction, formerly known as LIFELINE THERAPEUTICS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-22. Nothing here is a recommendation to trade the security.

Financial trend for Lifevantage Corp from annual reports, periods 2023-06-30 to 2026-06-30: net income (loss) went from $2.54 million (2023-06-30) to $5.07 million (2026-06-30), a change of +99.7%; total assets went from $66.12 million (2023-06-30) to $62.11 million (2026-06-30), a change of -6.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 849146, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Lifevantage Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Lifevantage Corp (CIK 849146) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-27, and the most recent 10-K annual report was filed 2026-08-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 194 8-K or 6-K reports in Lifevantage Corp’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1001 recent EDGAR filings, Lifevantage Corp most often filed 4 (522), 8-K (194), 10-Q (51), 3 (41). A selection from 2026-10-05 to 2026-10-22:

The full record for CIK 849146 is on the EDGAR company page; the latest 10-K there is dated 2026-08-27 and the oldest filing in the recent index dates from 2009-10-28. Insider trades for Lifevantage Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Manitowoc mtw latest news october 2026

This section ties “Manitowoc mtw latest news october 2026” to MANITOWOC CO INC (ticker MTW), SEC Central Index Key 61986, an EDGAR registrant classified as “Construction Machinery & Equip” and organised in WI. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-25. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-18 by MANITOWOC CO INC (CIK 61986) — source document:

The Manitowoc Company, Inc. (“Manitowoc” or the “Company”) was founded in 1902, and is headquartered in Milwaukee, Wisconsin, United States. Manitowoc, through its wholly-owned subsidiaries, provides high quality, customer-focused lifting products and services world-wide through its Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Upfits by Aspen Equipment brands and its support-focused subsidiary MGX Equipment Services. For more information, visit www.manitowoc.com. Reporting Segments The Company has three reportable segments; the Americas segment, the Europe and Africa (“EURAF”) segment, and the Middle East and Asia Pacific (“MEAP”) segment. The Americas reporting segment includes the North America and South America continents. The EURAF reporting segment includes the Europe and Africa continents, excluding the Middle East region.

Financial trend for MANITOWOC CO INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.03 billion (2022-12-31) to $2.24 billion (2025-12-31), a change of +10.3%; net income (loss) went from -$123.60 million (2022-12-31) to $7.20 million (2025-12-31), a change of +105.8%; total assets went from $1.62 billion (2022-12-31) to $1.82 billion (2025-12-31), a change of +12.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 61986, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures MANITOWOC CO INC did not tag for that period.

For the latest news, the fastest official source is the filing feed: MANITOWOC CO INC (CIK 61986) filed 145 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-25, and its overall latest filing is a 8-K dated 2026-08-25. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 145 8-K or 6-K reports in MANITOWOC CO INC’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-08-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 61986 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2014-01-09. Insider trades for MANITOWOC CO INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Meridian mining plc bullish and bearish analyst opinions

This section ties “Meridian mining plc bullish and bearish analyst opinions” to Meridian Corp (ticker MRBK), SEC Central Index Key 1750735, an EDGAR registrant classified as “National Commercial Banks” and organised in PA. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-13 by Meridian Corp (CIK 1750735) — source document:

The Corporation is a bank holding company engaged in banking activities through its wholly-owned subsidiary, Meridian Bank (the “Bank”), a full-service, state-chartered commercial bank with offices in the Delaware Valley tri-state market, which includes Pennsylvania, New Jersey and Delaware, as well as in the Central Maryland market, and southwest Florida. We have a financial services business model with non-interest revenue streams from mortgage banking, the sale of SBA loan guarantees and wealth management services. We provide services to small and middle market businesses, professionals and retail customers throughout our market area. We have a modern, progressive, consultative approach to creating innovative solutions for our customers. We are technology driven, with a culture that incorporates significant use of customer preferred alternative delivery channels, such as mobile banking, remote deposit capture and bank-to-bank ACH. Our ‘Meridian everywhere’ philosophy of community presence, along with our strategic business footprint, allows us to provide the high degree of service, convenience and products our customers need to achieve their financial objectives.

Financial trend for Meridian Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $4.73 million (2022-12-31) to $6.32 million (2025-12-31), a change of +33.4%; net income (loss) went from $21.83 million (2022-12-31) to $21.84 million (2025-12-31), a change of +0.0%; total assets went from $2.06 billion (2022-12-31) to $2.56 billion (2025-12-31), a change of +24.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1750735, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Meridian Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Meridian Corp (CIK 1750735) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-30, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 82 8-K or 6-K reports in Meridian Corp’s recent EDGAR index, the 4 listed here run from 2026-04-27 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1750735 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2018-08-24. Insider trades for Meridian Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Neurogene inc. bullish and bearish analyst opinions

This section ties “Neurogene inc. bullish and bearish analyst opinions” to Neurogene Inc. (ticker NGNE), SEC Central Index Key 1404644, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction, formerly known as Neoleukin Therapeutics, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-24 by Neurogene Inc. (CIK 1404644) — source document:

Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today’s complex devastating neurological diseases into treatable conditions. We are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy. One approach we are taking harnesses our proprietary transgene regulation technology, EXACT TM (Expression Attenuation via Construct Tuning), that utilizes microRNA-based genetic circuits designed to deliver therapeutic levels of transgene to key areas of the brain that underlie neurological disease pathology.

Financial trend for Neurogene Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2023-12-31) to $0 (2025-12-31); net income (loss) went from -$55.19 million (2022-12-31) to -$90.35 million (2025-12-31), a change of -63.7%; total assets went from $109.27 million (2022-12-31) to $288.60 million (2025-12-31), a change of +164.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1404644, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Neurogene Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Neurogene Inc. (CIK 1404644) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 148 8-K or 6-K reports in Neurogene Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-08 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1404644 is on the EDGAR company page; the latest 10-K there is dated 2026-03-24 and the oldest filing in the recent index dates from 2007-06-25. Insider trades for Neurogene Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Newel auctions leadership jake baer company news

What this search refers to. For company news on Newel’s leadership, the primary source is Newel’s own website and press coverage; as a private auction house it has no SEC filing obligation and appears in EDGAR only if it raises money through a Form D. Official source: www.newel.com.

No SEC filer could be matched to “Newel auctions leadership jake baer company news” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Newel auctions leadership jake baer company”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “newel” (search terms considered: newel, auctions, leadership, jake, baer).

Sample EDGAR registrant names, term by term — containing “newel”: NEWEL CORP (CIK 1911489); containing “auctions”: INSURANCE AUTO AUCTIONS TENNESSEE LLC (CIK 1513790), LIVEBLOCK AUCTIONS INTERNATIONAL, INC. (CIK 1441250), PREMIERE AUCTIONS GROUP, LLC (CIK 1644737); containing “leadership”: DIGITAL LEADERSHIP GROWTH PATH, INC. (CIK 1752051), DURATION VENTURES I LEADERSHIP PARTNERS LP (CIK 2155036), E 5 LEADERSHIP ACADEMY LLC (CIK 1757655); containing “jake”: FITZPATRICK JAKE JOHN (CIK 1822511), GARN EJ JAKE (CIK 1184203), HIDDEN JAKE CHINA FUND LP (CIK 1346878); containing “baer”: BAER CHRISTOPHER ALLEN (CIK 2025055), BAER DANIEL BROOKS (CIK 1954239), BAER DAVID D (CIK 1193874). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

Leadership changes at a privately owned auction business such as Newel are not reported to the SEC: the 8-K item for officer departures and appointments (Item 5.02) applies only to registrants. For a privately held company, the usual sources are its own press releases and state business-entity records, which list registered agents and sometimes officers but not management biographies. A person named in such news can be checked on FINRA BrokerCheck only if they are a registered securities professional.

Updated Oct 25, 2026 ET

Nexgel, inc. bullish and bearish analyst opinions

This section ties “Nexgel, inc. bullish and bearish analyst opinions” to NEXGEL, INC. (ticker NXGL, NXGLW), SEC Central Index Key 1468929, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE, formerly known as NEXGEL, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-07. Nothing here is a recommendation to trade the security.

Financial trend for NEXGEL, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.05 million (2022-12-31) to $11.42 million (2025-12-31), a change of +457.7%; net income (loss) went from -$4.75 million (2022-12-31) to -$3.00 million (2025-12-31), a change of +36.8%; total assets went from $10.36 million (2022-12-31) to $10.46 million (2025-12-31), a change of +1.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1468929, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures NEXGEL, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on NEXGEL, INC. (CIK 1468929) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-17, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 94 8-K or 6-K reports in NEXGEL, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-21 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 327 recent EDGAR filings, NEXGEL, INC. most often filed 4 (95), 8-K (94), 10-Q (22), 3 (15). A selection from 2026-08-17 to 2026-09-30:

The full record for CIK 1468929 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2009-08-28. Insider trades for NEXGEL, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Niagen bioscience inc bullish and bearish analyst opinions

This section ties “Niagen bioscience inc bullish and bearish analyst opinions” to Niagen Bioscience, Inc. (ticker NAGE), SEC Central Index Key 1386570, an EDGAR registrant classified as “Medicinal Chemicals & Botanical Products” and organised in DE, formerly known as ChromaDex Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-04. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-04 by Niagen Bioscience, Inc. (CIK 1386570) — source document:

Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc. and its consolidated subsidiaries. Company Background On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).

Financial trend for Niagen Bioscience, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $72.05 million (2022-12-31) to $129.42 million (2025-12-31), a change of +79.6%; net income (loss) went from -$16.54 million (2022-12-31) to $17.38 million (2025-12-31), a change of +205.1%; total assets went from $54.06 million (2022-12-31) to $106.41 million (2025-12-31), a change of +96.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1386570, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Niagen Bioscience, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Niagen Bioscience, Inc. (CIK 1386570) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-04, and the most recent 10-K annual report was filed 2026-03-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 233 8-K or 6-K reports in Niagen Bioscience, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-19 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1386570 is on the EDGAR company page; the latest 10-K there is dated 2026-03-04 and the oldest filing in the recent index dates from 2007-01-18. Insider trades for Niagen Bioscience, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Onemednet corporation bullish and bearish analyst opinions

This section ties “Onemednet corporation bullish and bearish analyst opinions” to OneMedNet Corp (ticker ONMD, ONMDW), SEC Central Index Key 1849380, an EDGAR registrant classified as “Services-Commercial Physical & Biological Research” and organised in DE, formerly known as Data Knights Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-14. Nothing here is a recommendation to trade the security.

Financial trend for OneMedNet Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.02 million (2023-12-31) to $1.36 million (2025-12-31), a change of +33.1%; net income (loss) went from -$30.45 million (2022-12-31) to -$2.80 million (2025-12-31), a change of +90.8%; total assets went from $1.29 million (2022-12-31) to $2.15 million (2025-12-31), a change of +66.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1849380, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures OneMedNet Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on OneMedNet Corp (CIK 1849380) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-05-23, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 68 8-K or 6-K reports in OneMedNet Corp’s recent EDGAR index, the 4 listed here run from 2026-07-24 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 289 recent EDGAR filings, OneMedNet Corp most often filed 8-K (68), 4 (28), 425 (19), 3 (18). A selection from 2026-09-30 to 2026-10-13:

The full record for CIK 1849380 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2021-03-09. Insider trades for OneMedNet Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Phio pharmaceuticals corp. bullish and bearish analyst opinions

This section ties “Phio pharmaceuticals corp. bullish and bearish analyst opinions” to Phio Pharmaceuticals Corp. (ticker PHIO), SEC Central Index Key 1533040, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as RXi Pharmaceuticals Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by Phio Pharmaceuticals Corp. (CIK 1533040) — source document:

Phio Pharmaceuticals Corp. (“ Phio ,” “ we ,” “ our ” or the “ Company ”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment and a single reportable segment.

Financial trend for Phio Pharmaceuticals Corp. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$11.48 million (2022-12-31) to -$8.70 million (2025-12-31), a change of +24.2%; total assets went from $12.81 million (2022-12-31) to $21.49 million (2025-12-31), a change of +67.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1533040, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Phio Pharmaceuticals Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Phio Pharmaceuticals Corp. (CIK 1533040) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 193 8-K or 6-K reports in Phio Pharmaceuticals Corp.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1533040 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2011-10-25. Insider trades for Phio Pharmaceuticals Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pomdoctor ltd bullish and bearish analyst opinions

This section ties “Pomdoctor ltd bullish and bearish analyst opinions” to POMDOCTOR Ltd (ticker POM), SEC Central Index Key 1877971, an EDGAR registrant classified as “Retail-Miscellaneous Retail” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-19, and this view starts from filings dated on or before 2026-08-03. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-05-14 by POMDOCTOR Ltd (CIK 1877971) (passage 2, continuing from the earlier excerpt) — source document:

In August 2021, Guangzhou WFOE entered into a series of agreements with Qilekang Digital Health and the shareholders of Qilekang Digital Health (except for Zhongke Baiyun). In October 2023, we terminated the contractual arrangements with General Technology Group Investment Management Co., Ltd., or General Technology. In the same month, we terminated the relevant agreements with Mr. Zhenyang Shi and Ms. Li Xu, with Guangzhou WFOE entering into a new series of agreements with Qilekang Digital Health and each of Mr. Zhenyang Shi and Ms. Li Xu, Guangzhou Jin Pin, Guangzhou Jin Shang, Guangzhou Jin Yue, and Guangzhou Jin Qiu. The agreements enable us to obtain control over Qilekang Digital Health through Guangzhou WFOE. As a result of the VIE Arrangements, the VIE is not our majority owned subsidiary, but we still are and will be the primary beneficiary of the VIE for accounting purpose only, and only to the extent that we satisfy the conditions required for consolidation of the VIE under U.S. GAAP. We treated the VIE and its subsidiaries as our consolidated affiliated entities under generally accepted accounting principles in the United States, or U.S.

Financial trend for POMDOCTOR Ltd from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from 304,852,971 CNY (2023-12-31) to 399,914,964 CNY (2025-12-31), a change of +31.2%; net income (loss) went from -36,949,421 CNY (2023-12-31) to -130,931,921 CNY (2025-12-31), a change of -254.4%; total assets went from 46,227,586 CNY (2024-12-31) to 107,557,426 CNY (2025-12-31), a change of +132.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1877971, tags Assets, ProfitLoss, Revenues; 3 periods shown, dashes mark figures POMDOCTOR Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on POMDOCTOR Ltd (CIK 1877971) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 24 8-K or 6-K reports in POMDOCTOR Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-04 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1877971 is on the EDGAR company page; the latest 20-F there is dated 2026-05-14 and the oldest filing in the recent index dates from 2021-09-30. One example from this record is the 6-K filed 2026-09-29 (document). Insider trades for POMDOCTOR Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Prenetics global limited bullish and bearish analyst opinions

This section ties “Prenetics global limited bullish and bearish analyst opinions” to Prenetics Global Ltd (ticker PRE, PRENW), SEC Central Index Key 1876431, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-30 by Prenetics Global Ltd (CIK 1876431) — source document:

Prenetics was founded in 2014 in Hong Kong by Danny Yeung and has evolved—through a series of deliberate strategic pivots—from a genomic testing company into a consumer health and longevity platform. IM8 was co-founded with David Beckham and launched in December 2024. Its performance in FY2025 accelerated a strategic conclusion: Prenetics would become a consumer health company, and IM8 would be its engine. In January 2025, IM8 generated $1 million in monthly revenue. By December 2025, that figure was $10 million. In twelve months, a newly launched brand produced $60.1 million in revenue and reached $120 million in annualized recurring revenue 1 ("ARR")—a trajectory that, to our knowledge, is without precedent in the global supplement industry.

Financial trend for Prenetics Global Ltd from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from $12.53 million (2021-12-31) to $21.74 million (2023-12-31), a change of +73.5%; net income (loss) went from -$174.02 million (2021-12-31) to -$49.81 million (2024-12-31), a change of +71.4%; total assets went from $148.51 million (2021-12-31) to $213.57 million (2024-12-31), a change of +43.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1876431, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Prenetics Global Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Prenetics Global Ltd (CIK 1876431) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in Prenetics Global Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-18 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1876431 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2021-09-16. Insider trades for Prenetics Global Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Prestige consumer healthcare pbh news october 2026

This section ties “Prestige consumer healthcare pbh news october 2026” to Prestige Consumer Healthcare Inc. (ticker PBH), SEC Central Index Key 1295947, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in an unstated jurisdiction, formerly known as Prestige Brands Holdings, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-14, and this view starts from filings dated on or before 2026-07-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-05-14 by Prestige Consumer Healthcare Inc. (CIK 1295947) (passage 2, continuing from the earlier excerpt) — source document:

We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage. Our ultimate success is dependent on several factors, including our ability to: • Develop and execute effective sales, advertising and marketing programs to maintain or grow our market share versus competitors over time; • Establish and maintain our internal and third-party manufacturing and distribution relationships to fulfill customer demands; • Develop innovative new products; • Continue to grow our presence in the United States and international markets through acquisitions and organic growth; and • Allocate capital effectively. We have grown our product portfolio both organically and through acquisitions.

Financial trend for Prestige Consumer Healthcare Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $42.21 million (2025-09-30) to $29.18 million (2026-06-30), a change of -30.9%; total assets went from $3.44 billion (2025-09-30) to $4.57 billion (2026-06-30), a change of +32.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1295947, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Prestige Consumer Healthcare Inc. did not tag for that period.

Current reports. Of the 157 8-K or 6-K reports in Prestige Consumer Healthcare Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-05 to 2026-06-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1295947 is on the EDGAR company page; the latest 10-K there is dated 2026-05-14 and the oldest filing in the recent index dates from 2008-11-06. One example from this record is the 4 filed 2026-08-05 (document). Insider trades for Prestige Consumer Healthcare Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Primeenergy resources corporation bullish and bearish analyst opinions

This section ties “Primeenergy resources corporation bullish and bearish analyst opinions” to PRIMEENERGY RESOURCES CORP (ticker PNRG), SEC Central Index Key 56868, an EDGAR registrant classified as “Crude Petroleum & Natural Gas” and organised in DE, formerly known as PRIMEENERGY CORP. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4/A dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-16 by PRIMEENERGY RESOURCES CORP (CIK 56868) — source document:

PrimeEnergy Resources Corporation (the “Company”) was organized in March 1973, under the laws of the State of Delaware. We are an independent oil and natural gas company engaged in acquiring, developing, and producing oil and natural gas. We presently own producing and non-producing properties located primarily in Texas, and Oklahoma. All of our oil and gas properties and interests are located in the United States. Through our subsidiaries Prime Operating Company and EOWS Midland Company, we act as operator and provide well-servicing support operations for many of the onshore oil and gas wells we operate, as well as for third parties. We are also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.

Financial trend for PRIMEENERGY RESOURCES CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $157.11 million (2022-12-31) to $189.05 million (2025-12-31), a change of +20.3%; net income (loss) was tagged only for 2022-12-31 at $48.66 million; total assets went from $247.14 million (2022-12-31) to $323.89 million (2025-12-31), a change of +31.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 56868, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures PRIMEENERGY RESOURCES CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PRIMEENERGY RESOURCES CORP (CIK 56868) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 42 8-K or 6-K reports in PRIMEENERGY RESOURCES CORP’s recent EDGAR index, the 4 listed here run from 2025-07-01 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 56868 is on the EDGAR company page; the latest 10-K there is dated 2026-04-16 and the oldest filing in the recent index dates from 1995-04-13. Insider trades for PRIMEENERGY RESOURCES CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pt diamond food indonesia tbk bullish and bearish analyst opinions

Read from its name, “Pt diamond food indonesia tbk” is a Indonesia entity — “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. Its accounts and exchange notices are published through the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Pt diamond food indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pt diamond food indonesia tbk”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “diamond” (search terms considered: diamond, food, indonesia).

Even the shorter phrase “Pt diamond food” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (diamond, food, indonesia) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “diamond” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 183+ entities whose registered name contains the word “diamond”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “diamond” 474, “food” 480, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “diamond” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt inter delta tbk bullish and bearish analyst opinions

“PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. The name “Pt inter delta tbk” therefore points to a company organised in Indonesia, and its official disclosures are on the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id), not on EDGAR.

No SEC filer could be matched to “Pt inter delta tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pt inter delta tbk”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “inter” (search terms considered: inter, delta).

Even the shorter phrase “Pt inter delta” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (inter, delta) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “inter” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 88 entities whose registered name contains the word “inter”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “inter” 88, “delta” 398. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “inter” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt pp (persero) tbk bullish and bearish analyst opinions

The legal-form ending in “Pt pp (persero) tbk” is the clue: “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. A company of that kind reports in Indonesia, so the place to read its annual report and announcements is the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK — www.idx.co.id.

No SEC filer could be matched to “Pt pp (persero) tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Pt pp persero tbk” appears in 394+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “persero” (search terms considered: persero).

A broader EDGAR full-text search for the shorter phrase “Pt pp tbk” finds 3 filing documents; among the top 3, the filers mentioning it most are EATON VANCE MUTUAL FUNDS TRUST (CIK 0000745463) (1); JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 0000756913) (1); John Hancock Funds II (CIK 0001331971) (1). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “persero” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Pt pp persero tbk”, filings range from 2013-08-21 to 2026-08-25. The filers whose documents mention it most often are THRIVENT MUTUAL FUNDS (CIK 0000811869) (24 hits); JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 0000756913) (19 hits); John Hancock Funds II (CIK 0001331971) (18 hits); Thrivent Core Funds (CIK 0001669626) (9 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 10 entities whose registered name contains the word “persero”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “persero” 10. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “persero” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Resideo technologies rezi latest news october 2026

This section ties “Resideo technologies rezi latest news october 2026” to RESIDEO TECHNOLOGIES, INC. (ticker REZI), SEC Central Index Key 1740332, an EDGAR registrant classified as “Wholesale-Hardware” and organised in DE, formerly known as RESIDEO TECHNOLOGIES, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 144 dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-24 by RESIDEO TECHNOLOGIES, INC. (CIK 1740332) — source document:

As used herein, unless the context otherwise dictates, the term “Resideo”, the “Company”, “we”, “us”, or “our” means Resideo Technologies, Inc. and its consolidated subsidiaries. Our common stock began trading under the ticker symbol “REZI” on the New York Stock Exchange (“NYSE”) on October 29, 2018. We separated from Honeywell International Inc. (“Honeywell”) in 2018, becoming an independent publicly traded company as a result of a pro rata distribution of our common stock to stockholders of Honeywell (the “Honeywell Spin-Off”). Description of Business We are a global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions that help homeowners and businesses stay connected and in control of their comfort, security, energy use, and smart living.

Financial trend for RESIDEO TECHNOLOGIES, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $6.37 billion (2022-12-31) to $7.47 billion (2025-12-31), a change of +17.3%; net income (loss) went from $283.00 million (2022-12-31) to -$527.00 million (2025-12-31), a change of -286.2%; total assets went from $6.39 billion (2022-12-31) to $8.43 billion (2025-12-31), a change of +32.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1740332, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures RESIDEO TECHNOLOGIES, INC. did not tag for that period.

For the latest news, the fastest official source is the filing feed: RESIDEO TECHNOLOGIES, INC. (CIK 1740332) filed 99 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-12, and its overall latest filing is a 144 dated 2026-10-20. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 99 8-K or 6-K reports in RESIDEO TECHNOLOGIES, INC.’s recent EDGAR index, the 4 listed here run from 2026-07-13 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1740332 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2018-06-14. Insider trades for RESIDEO TECHNOLOGIES, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Reuters/edgar su

What this search refers to. “Reuters/edgar su” is a truncated research query combining the Reuters news service with SEC EDGAR, not a company name; EDGAR full-text search is the official tool for finding filings by keyword. Official source: efts.sec.gov.

No SEC filer could be matched to “Reuters/edgar su” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Reuters/edgar su”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “reuters” (search terms considered: reuters, edgar).

Even the shorter phrase “Reuters edgar su” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (reuters, edgar) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 9 entities whose registered name contains the word “reuters”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “reuters” 9, “edgar” 137. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “reuters”: DSC THOMSON REUTERS PE INDEX PARTNERS, L.P. (CIK 1596251), DSC THOMSON REUTERS PE/VC INDEX PARTNERS, L.P. (CIK 1559325), REUTERS GLOBAL ROUTING SERVICES US LLC (CIK 714552); containing “edgar”: ALLEN TEST EDGAR RELEASE 440 (CIK 849486), ANCONA EDGAR D (CIK 1471402), ANDERSON EDGAR A. (CIK 1486700). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “reuters” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Solid power sldp latest news october 2026

This section ties “Solid power sldp latest news october 2026” to Solid Power, Inc. (ticker SLDP, SLDPW), SEC Central Index Key 1844862, an EDGAR registrant classified as “Miscellaneous Electrical Machinery, Equipment & Supplies” and organised in DE, formerly known as Decarbonization Plus Acquisition Corp III. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-01. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-25 by Solid Power, Inc. (CIK 1844862) — source document:

Solid Power is a U.S.-based leader in solid-state battery technology and manufacturing processes. Our core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. We believe our electrolyte technology has the potential to enable a step-change improvement in battery cell performance beyond what is currently achievable in conventional lithium-ion battery cells, including improved energy density, battery life, and safety performance. We are currently targeting the battery electric vehicle (“EV”) market due to the size and perceived demand for next generation battery technology but believe our technologies can have a broader application as the technologies mature. Commercialization Strategy Our commercialization strategy is to manufacture and sell electrolyte to Tier 1 battery manufacturers and automotive original equipment manufacturers (“OEMs”) that choose to produce their own battery cells.

Financial trend for Solid Power, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $11.79 million (2022-12-31) to $21.75 million (2025-12-31), a change of +84.5%; net income (loss) went from -$9.55 million (2022-12-31) to -$93.41 million (2025-12-31), a change of -877.6%; total assets went from $594.45 million (2022-12-31) to $455.09 million (2025-12-31), a change of -23.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1844862, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Solid Power, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Solid Power, Inc. (CIK 1844862) filed 81 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-14, and its overall latest filing is a 4 dated 2026-10-01. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 81 8-K or 6-K reports in Solid Power, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-12 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1844862 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2021-02-12. Insider trades for Solid Power, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Solid power sldp news

This section ties “Solid power sldp news” to Solid Power, Inc. (ticker SLDP, SLDPW), SEC Central Index Key 1844862, an EDGAR registrant classified as “Miscellaneous Electrical Machinery, Equipment & Supplies” and organised in DE, formerly known as Decarbonization Plus Acquisition Corp III. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-01, and this view starts from filings dated on or before 2026-07-01. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-25 by Solid Power, Inc. (CIK 1844862) (passage 2, continuing from the earlier excerpt) — source document:

We also intend to pursue licensing arrangements for our cell manufacturing processes and cell designs. This business model distinguishes us from competitors who are, or plan to be, commercial battery manufacturers and allows us to focus on our core strength of electrolyte development and production. Since we do not plan to produce commercial battery cells, we expect to have significantly lower capital requirements than cell manufacturers. Technologies and Pilot Manufacturing Our electrolyte is a sulfide-based material comprised of lithium sulfide (“Li2S”) and other inputs. We believe most OEMs and battery manufacturers have a technology roadmap that includes sulfide-based, solid-state cell products that can utilize our electrolyte. Our electrolyte is made from abundant materials produced at industrial scale in multiple geographical locations, except for the Li2S precursor material.

Financial trend for Solid Power, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $4.56 million (2025-09-30) to -$268,000 (2026-06-30), a change of -105.9%; net income (loss) went from -$25.87 million (2025-09-30) to -$23.82 million (2026-06-30), a change of +7.9%; total assets went from $416.14 million (2025-09-30) to $527.07 million (2026-06-30), a change of +26.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1844862, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Solid Power, Inc. did not tag for that period.

Current reports. Of the 81 8-K or 6-K reports in Solid Power, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-24 to 2026-05-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1844862 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2021-02-12. One example from this record is the SCHEDULE 13G/A filed 2026-08-14 (document). Insider trades for Solid Power, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tcpc blackrock tcp capital latest news

This section ties “Tcpc blackrock tcp capital latest news” to BlackRock TCP Capital Corp. (ticker TCPC), SEC Central Index Key 1370755, an EDGAR registrant classified as “no SIC description” and organised in DE, formerly known as TCP Capital Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 40-17G dated 2026-10-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by BlackRock TCP Capital Corp. (CIK 1370755) — source document:

In this annual report in Form 10-K, except as otherwise indicated, the terms: “Company,” "we," "us" and "our" refer to Special Value Continuation Fund, LLC, a Delaware limited liability company, for the periods prior to the consummation of the Conversion described elsewhere in this report and to BlackRock TCP Capital Corp., formerly known as TCP Capital Corp., for the periods after the consummation of the Conversion; “SVCP” refers to Special Value Continuation Partners LLC, a Delaware limited liability company; “TCPC Funding” refers to TCPC Funding I, LLC, a Delaware limited liability company; “TCPC Funding II” refers to TCPC Funding II, LLC, a Delaware limited liability company; The “SBIC” refers to TCPC SBIC, LP, a Delaware limited partnership; "Merger Sub" refers to BCIC Merger Sub, LLC, a Delaware limited liability company; The “Advisor” refers to Tennenbaum Capital Partners, LLC, a Delaware limited liability company and the investment manager; and “Administrator” refers to Series H of SVOF/MM, LLC, a series of a Delaware limited liability company, an affiliate of the Advisor and administrator of the Company.

Financial trend for BlackRock TCP Capital Corp. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$9.23 million (2022-12-31) to -$88.93 million (2025-12-31), a change of -864.0%; total assets went from $1.72 billion (2022-12-31) to $1.65 billion (2025-12-31), a change of -4.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1370755, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures BlackRock TCP Capital Corp. did not tag for that period.

For the latest news, the fastest official source is the filing feed: BlackRock TCP Capital Corp. (CIK 1370755) filed 151 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-25, and its overall latest filing is a 40-17G dated 2026-10-15. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 151 8-K or 6-K reports in BlackRock TCP Capital Corp.’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1370755 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2006-08-01. Insider trades for BlackRock TCP Capital Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Trinity insurance services wpc

What this search refers to. “Trinity insurance services wpc” names an insurance agency; agencies and producers are licensed by state insurance departments, which the NAIC’s consumer information system links to. Official source: content.naic.org.

No SEC filer could be matched to “Trinity insurance services wpc” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Trinity insurance services wpc”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “trinity” (search terms considered: trinity, insurance, services, wpc).

Even the shorter phrase “Trinity insurance services” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (trinity, insurance, services, wpc) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 194+ entities whose registered name contains the word “trinity”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “trinity” 395, “insurance” 481, “services” 472, “wpc” 13. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “trinity”: 1041 EAST TRINITY LP, LLC (CIK 1762532), 2013 BAYOU CITY TRINITY BAY DRILLING PROGRAM, L.P. (CIK 1577217), 2700 TRINITY LLC (CIK 1960207); containing “insurance”: 1347 PROPERTY INSURANCE HOLDINGS, INC. (CIK 1591890), 180 INSURANCE LTD. (CIK 1865078), 1997 ANTEBI CHILDRENS INSURANCE & OTHER TRUST (CIK 1098688); containing “services”: 1 4 SURGICAL SERVICES LLC (CIK 1229382), 1 NORTH WEALTH SERVICES LLC (CIK 1641761), 1 SOURCE LAB & MEDICAL SERVICES, LLC (CIK 1754517); containing “wpc”: WPC - POCKET NALOXONE APR 2022 A SERIES OF CGF2021 LLC (CIK 1934338), WPC - PROMAXO 2022 A SERIES OF CGF2021 LLC (CIK 1931072), WPC 2004 COPPELL LP (CIK 1313502). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “trinity” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Turkcell iletisim hizmetleri a.s. bullish and bearish analyst opinions

This section ties “Turkcell iletisim hizmetleri a.s. bullish and bearish analyst opinions” to TURKCELL ILETISIM HIZMETLERI A S (ticker TKC), SEC Central Index Key 1071321, an EDGAR registrant classified as “Telephone Communications (No Radiotelephone)” and organised in Turkey. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for TURKCELL ILETISIM HIZMETLERI A S from annual reports, periods 2020-12-31 to 2023-12-31: revenue went from 69,502,765,000 TRY (2020-12-31) to 107,116,184,000 TRY (2023-12-31), a change of +54.1%; net income (loss) went from 4,508,466,000 TRY (2020-12-31) to 12,532,246,000 TRY (2023-12-31), a change of +178.0%; total assets went from 51,498,393,000 TRY (2020-12-31) to 247,083,325,000 TRY (2023-12-31), a change of +379.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1071321, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures TURKCELL ILETISIM HIZMETLERI A S did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TURKCELL ILETISIM HIZMETLERI A S (CIK 1071321) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 881 8-K or 6-K reports in TURKCELL ILETISIM HIZMETLERI A S’s recent EDGAR index, the 4 listed here run from 2026-10-09 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, TURKCELL ILETISIM HIZMETLERI A S most often filed 6-K (881), 3 (26), SC 13D/A (25), 20-F (17). A selection from 2026-04-17 to 2026-09-15:

The full record for CIK 1071321 is on the EDGAR company page; the latest 20-F there is dated 2026-04-17 and the oldest filing in the recent index dates from 2010-01-04. Insider trades for TURKCELL ILETISIM HIZMETLERI A S appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Upbound group upbd latest news october 2026

This section ties “Upbound group upbd latest news october 2026” to UPBOUND GROUP, INC. (ticker UPBD), SEC Central Index Key 933036, an EDGAR registrant classified as “Services-Equipment Rental & Leasing, NEC” and organised in DE, formerly known as RENT A CENTER INC DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-08. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-23 by UPBOUND GROUP, INC. (CIK 933036) — source document:

Unless the context indicates otherwise, references to “we,” “us”, “our”, and the “Company” refer to the consolidated business operations of Upbound Group, Inc., the parent, and any or all of its direct and indirect subsidiaries. For any references in this document to Note A through Note U, refer to the Notes to consolidated financial statements in Item 8 included in this Annual Report on Form 10-K. We are a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers. Through our Acima and Rent-A-Center segments, we are a leading lease-to-own provider with operations in the United States, Puerto Rico and Mexico.

Financial trend for UPBOUND GROUP, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $4.25 billion (2022-12-31) to $4.70 billion (2025-12-31), a change of +10.6%; net income (loss) went from $12.36 million (2022-12-31) to $73.24 million (2025-12-31), a change of +492.7%; total assets went from $2.76 billion (2022-12-31) to $3.28 billion (2025-12-31), a change of +18.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 933036, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures UPBOUND GROUP, INC. did not tag for that period.

For the latest news, the fastest official source is the filing feed: UPBOUND GROUP, INC. (CIK 933036) filed 172 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-22, and its overall latest filing is a SCHEDULE 13G dated 2026-10-08. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 172 8-K or 6-K reports in UPBOUND GROUP, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 933036 is on the EDGAR company page; the latest 10-K there is dated 2026-02-23 and the oldest filing in the recent index dates from 2015-02-03. Insider trades for UPBOUND GROUP, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Veraxa biotech holding ag bullish and bearish analyst opinions

This section ties “Veraxa biotech holding ag bullish and bearish analyst opinions” to Veraxa Biotech AG - Post de-SPAC (ticker VRXA, VRXAW), SEC Central Index Key 2079109, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Switzerland, formerly known as Veraxa Biotech Holding AG. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-21. Nothing here is a recommendation to trade the security.

Analyst ratings, price targets and “bullish” or “bearish” calls on Veraxa Biotech AG - Post de-SPAC (CIK 2079109) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-06-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 8 8-K or 6-K reports in Veraxa Biotech AG - Post de-SPAC’s recent EDGAR index, the 4 listed here run from 2026-07-31 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 55 recent EDGAR filings, Veraxa Biotech AG - Post de-SPAC most often filed 3 (9), 6-K (8), F-4/A (5), SCHEDULE 13D (4). A selection from 2026-08-31 to 2026-10-21:

The full record for CIK 2079109 is on the EDGAR company page; the latest 20-F there is dated 2026-06-16 and the oldest filing in the recent index dates from 2025-07-31. Insider trades for Veraxa Biotech AG - Post de-SPAC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Viking supply ships ab (publ) bullish and bearish analyst opinions

“AB (publ)” marks a Swedish public limited company (aktiebolag) allowed to offer shares to the public. The name “Viking supply ships ab (publ)” therefore points to a company organised in Sweden, and its official disclosures are on Nasdaq Stockholm / Spotlight announcements and the Swedish FSA (Finansinspektionen) register (www.fi.se), not on EDGAR.

No SEC filer could be matched to “Viking supply ships ab (publ) bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Viking supply ships ab publ”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “viking” (search terms considered: viking, supply, ships).

A broader EDGAR full-text search for the shorter phrase “Viking supply ships” finds 26 filing documents; among the top 26, the filers mentioning it most are TRICO MARINE SERVICES INC (CIK 0000921549) (21); Kistefos AS (CIK 0001321465) (14); Gabelli Global Small & Mid Cap Value Trust (GGZ) (CIK 0001585855) (3). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Sweden. Companies there file with Nasdaq Stockholm and Finansinspektionen rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “viking” is therefore the Sweden regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 144 entities whose registered name contains the word “viking”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “viking” 144, “supply” 352, “ships” 16. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “viking” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Virax biolabs group limited bullish and bearish analyst opinions

This section ties “Virax biolabs group limited bullish and bearish analyst opinions” to Virax Biolabs Group Ltd (ticker VRAX), SEC Central Index Key 1885827, an EDGAR registrant classified as “In Vitro & In Vivo Diagnostic Substances” and organised in Cayman Islands, formerly known as Virax Biolabs (Cayman) Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 3 dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-07-06 by Virax Biolabs Group Ltd (CIK 1885827) — source document:

Our principal executive offices are located at BioCity Glasgow, Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH. Our telephone number is +44 020 7788 7414. Virax Biolabs is a holding company incorporated in the Cayman Islands. In June 2022, Virax Cayman underwent a shareholding restructuring whereby the Company’s authorized share capital became a single class of ordinary shares and all of the then issued shares were re-designated as ordinary shares. In July 2022, the Company completed its IPO and began trading on the Nasdaq under the symbol “VRAX.” We had $255,831 and $603,890 of capital expenditures associated with the purchase of property, plant and equipment for the year ended March 31, 2026 and 2025, respectively.

Financial trend for Virax Biolabs Group Ltd from annual reports, periods 2022-03-31 to 2025-03-31: net income (loss) went from -$1.75 million (2022-03-31) to -$6.07 million (2025-03-31), a change of -246.7%; total assets went from $48,706 (2022-03-31) to $6.43 million (2025-03-31), a change of +13095.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1885827, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Virax Biolabs Group Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Virax Biolabs Group Ltd (CIK 1885827) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-07-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 73 8-K or 6-K reports in Virax Biolabs Group Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-18 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1885827 is on the EDGAR company page; the latest 20-F there is dated 2026-07-06 and the oldest filing in the recent index dates from 2021-12-27. Insider trades for Virax Biolabs Group Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wilco 63 corporation bullish and bearish analyst opinions

This section ties “Wilco 63 corporation bullish and bearish analyst opinions” to Wilco 63 Corp (ticker WLCO, WLCOU, WLCOW), SEC Central Index Key 2101470, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for Wilco 63 Corp from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$15,485 (2026-03-31) to $98,597 (2026-06-30), a change of +736.7%; total assets was tagged only for 2026-06-30 at $230.56 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2101470, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Wilco 63 Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Wilco 63 Corp (CIK 2101470) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 3 8-K or 6-K reports in Wilco 63 Corp’s recent EDGAR index, the 3 listed here run from 2026-06-24 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 23 recent EDGAR filings, Wilco 63 Corp most often filed 3 (7), SCHEDULE 13G (6), 8-K (3), 10-Q (1). A selection from 2026-07-07 to 2026-08-14:

The full record for CIK 2101470 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-26. Insider trades for Wilco 63 Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Willis towers watson india insurance broker pvt ltd mobile apps

“Willis towers watson india insurance broker pvt ltd” is searched here together with “mobile apps”, so the question is which apps the business publishes, not its SEC record. App listings show the developer’s legal name; the authoritative places to check are Google Play’s developer search and Apple’s App Store, where an app published by Willis towers watson india insurance broker pvt ltd would show that exact name under “Developer” or “Seller”.

No SEC filer could be matched to “Willis towers watson india insurance broker pvt ltd mobile apps” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Willis towers watson india insurance broker”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “willis” (search terms considered: willis, towers, watson, india, insurance, broker, pvt).

A broader EDGAR full-text search for the shorter phrase “Willis towers watson” finds 10000+ filing documents; among the top 100, the filers mentioning it most are WILLIS TOWERS WATSON PLC (WTW) (CIK 0001140536) (85); WILLIS NORTH AMERICA INC (CIK 0001081003) (12); WILLIS GROUP LTD (CIK 0001081009) (12). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in India. Companies there file with NSE/BSE and the Securities and Exchange Board of India (SEBI) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “willis” is therefore the India regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 158 entities whose registered name contains the word “willis”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “willis” 158, “towers” 130, “watson” 267, “india” 472, “insurance” 481, “broker” 49. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

Aardvark therapeutics, inc. common stock bullish and bearish analyst opinions

This section ties “Aardvark therapeutics, inc. common stock bullish and bearish analyst opinions” to Aardvark Therapeutics, Inc. (ticker AARD), SEC Central Index Key 1774857, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Aardvark Therapeutics, Inc. from annual reports, periods 2024-12-31 to 2025-12-31: revenue was tagged only for 2025-12-31 at $0; net income (loss) went from -$20.59 million (2024-12-31) to -$57.59 million (2025-12-31), a change of -179.7%; total assets went from $77.51 million (2024-12-31) to $117.18 million (2025-12-31), a change of +51.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1774857, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 2 periods shown, dashes mark figures Aardvark Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aardvark Therapeutics, Inc. (CIK 1774857) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 25 8-K or 6-K reports in Aardvark Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-17 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 114 recent EDGAR filings, Aardvark Therapeutics, Inc. most often filed 4 (31), 8-K (25), 3 (12), 144 (5). A selection from 2026-09-10 to 2026-10-08:

The full record for CIK 1774857 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2019-05-24. Insider trades for Aardvark Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Abony acquisition corp. i units bullish and bearish analyst opinions

This section ties “Abony acquisition corp. i units bullish and bearish analyst opinions” to Abony Acquisition Corp. I (ticker AACO, AACOU, AACOW), SEC Central Index Key 2099906, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-11, and this view starts from filings dated on or before 2026-02-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Abony Acquisition Corp. I (CIK 2099906) (passage 2, continuing from the earlier excerpt) — source document:

The registration statement for the Company’s initial public offering was declared effective on January 30, 2026. On February 20, 2026, we completed our initial public offering, which consisted of 23,000,000 units each comprising one Class A Share and one-third of one whole public warrant to purchase one Class A Share, including the exercise in full by the underwriter of an option to purchase up to 3,000,000 units at the offering price to cover over-allotments. The units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $230,000,000. Also, on February 20, 2026, simultaneously with the consummation of our initial public offering, we completed the private sale of an aggregate of 695,000 units to our sponsor and BTIG at a purchase price of $10.00 per private placement unit, generating gross proceeds to the Company of $6,950,000.

Analyst ratings, price targets and “bullish” or “bearish” calls on Abony Acquisition Corp. I (CIK 2099906) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Other filings. Across its 26 recent EDGAR filings, Abony Acquisition Corp. I most often filed 3 (6), SCHEDULE 13G (3), 8-K (3), 10-Q (2). A selection from 2026-02-18 to 2026-02-24:

The full record for CIK 2099906 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2025-12-29. One example from this record is the 8-K filed 2026-04-08 (document). Insider trades for Abony Acquisition Corp. I appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Accendra health, inc. bullish and bearish analyst opinions

This section ties “Accendra health, inc. bullish and bearish analyst opinions” to ACCENDRA HEALTH INC/VA/ (ticker ACH), SEC Central Index Key 75252, an EDGAR registrant classified as “Wholesale-Medical, Dental & Hospital Equipment & Supplies” and organised in VA, formerly known as OWENS & MINOR INC/VA/. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a PRE 14A dated 2026-10-19, and this view starts from filings dated on or before 2026-08-10. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-20 by ACCENDRA HEALTH INC/VA/ (CIK 75252) (passage 2, continuing from the earlier excerpt) — source document:

On December 31, 2025, we completed the sale of the P&HS business pursuant to the Purchase Agreement. We have retained a 5% equity interest in the P&HS business. ​ Product Offering and Services We provide delivery of products, including disposable medical supplies sold directly to patients and home health agencies and are a leading provider of integrated home healthcare equipment and related services in the U.S. We offer a comprehensive range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services).

Financial trend for ACCENDRA HEALTH INC/VA/ from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $697.26 million (2025-09-30) to $613.23 million (2026-06-30), a change of -12.1%; net income (loss) went from -$150.28 million (2025-09-30) to -$89.07 million (2026-06-30), a change of +40.7%; total assets went from $4.04 billion (2025-09-30) to $2.11 billion (2026-06-30), a change of -47.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 75252, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures ACCENDRA HEALTH INC/VA/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ACCENDRA HEALTH INC/VA/ (CIK 75252) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-02-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 154 8-K or 6-K reports in ACCENDRA HEALTH INC/VA/’s recent EDGAR index, the 4 listed here run from 2026-06-15 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 75252 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2017-04-18. One example from this record is the 8-K/A filed 2026-09-28 (document). Insider trades for ACCENDRA HEALTH INC/VA/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Airgain, inc. bullish and bearish analyst opinions

This section ties “Airgain, inc. bullish and bearish analyst opinions” to AIRGAIN INC (ticker AIRG), SEC Central Index Key 1272842, an EDGAR registrant classified as “Radio & Tv Broadcasting & Communications Equipment” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-26 by AIRGAIN INC (CIK 1272842) — source document:

Headquartered in San Diego, California, Airgain, Inc. (NASDAQ: AIRG) is a leading provider of advanced wireless connectivity solutions. We are focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. Our mission is to connect the world through integrated, innovative, and optimized wireless solutions. Our diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software and cloud management. Our enterprise products include Smart Network Controlled Cellular Repeaters (Smart NCRs), embedded cellular modems, asset tracking solutions, and antennas for access points and Internet of Things (IoT) applications.

Financial trend for AIRGAIN INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $75.89 million (2022-12-31) to $51.78 million (2025-12-31), a change of -31.8%; net income (loss) went from -$8.66 million (2022-12-31) to -$6.43 million (2025-12-31), a change of +25.8%; total assets went from $54.40 million (2022-12-31) to $45.34 million (2025-12-31), a change of -16.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1272842, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures AIRGAIN INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AIRGAIN INC (CIK 1272842) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 87 8-K or 6-K reports in AIRGAIN INC’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1272842 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2003-12-10. Insider trades for AIRGAIN INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alterity therapeutics limited bullish and bearish analyst opinions

This section ties “Alterity therapeutics limited bullish and bearish analyst opinions” to ALTERITY THERAPEUTICS LTD (ticker ATHE, PRNAF), SEC Central Index Key 1131343, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Australia, formerly known as PRANA BIOTECHNOLOGY LTD. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-08-28 by ALTERITY THERAPEUTICS LTD (CIK 1131343) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 26 A. Operating Results 26 B. Liquidity and Capital Resources 29 C. Research and Development, Patents and Licenses 31 D. Trend Information 31 E. Critical Accounting Estimates 31 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 32 A. Directors and Senior Management 32 B. Compensation 33 C. Board Practices 39 D. Employees 41 E. Share Ownership 41 F. Disclosure of a registrant’s action to recover erroneously awarded compensation 45 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 45 A. Major Shareholders 45 B. Related Party Transactions 45 C. Interests of Experts and Counsel 45 ITEM 8. FINANCIAL INFORMATION 45 A. Financial Statements and Other Financial Information 45 B. Significant Changes 45 ITEM 9.

Financial trend for ALTERITY THERAPEUTICS LTD from annual reports, periods 2022-06-30 to 2025-06-30: net income (loss) went from -12,847,061 AUD (2022-06-30) to -12,147,828 AUD (2025-06-30), a change of +5.4%; total assets went from 41,362,611 AUD (2022-06-30) to 46,026,360 AUD (2025-06-30), a change of +11.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1131343, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures ALTERITY THERAPEUTICS LTD did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ALTERITY THERAPEUTICS LTD (CIK 1131343) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-08-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 864 8-K or 6-K reports in ALTERITY THERAPEUTICS LTD’s recent EDGAR index, the 4 listed here run from 2026-10-21 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1131343 is on the EDGAR company page; the latest 20-F there is dated 2026-08-28 and the oldest filing in the recent index dates from 2007-10-19. Insider trades for ALTERITY THERAPEUTICS LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Altisource portfolio solutions s.a. bullish and bearish analyst opinions

This section ties “Altisource portfolio solutions s.a. bullish and bearish analyst opinions” to ALTISOURCE PORTFOLIO SOLUTIONS S.A. (ticker ASPS, ASPSW, ASPSZ), SEC Central Index Key 1462418, an EDGAR registrant classified as “Services-Miscellaneous Business Services” and organised in Luxembourg, formerly known as Altisource Portfolio Solutions S.a.r.l.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-08-24. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-04 by ALTISOURCE PORTFOLIO SOLUTIONS S.A. (CIK 1462418) — source document:

Altisource ® is an integrated service provider and marketplace for the real estate and mortgage industries. Combining operational excellence with a suite of innovative services and technologies, Altisource helps solve the demands of the ever-changing markets we serve. We are publicly traded on the NASDAQ Global Select Market under the symbol “ASPS.” We are organized under the laws of the Grand Duchy of Luxembourg. We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Reportable Segments Our reportable segments are as follows: Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle.

Financial trend for ALTISOURCE PORTFOLIO SOLUTIONS S.A. from annual reports, periods 2022-12-31 to 2025-12-31: total assets went from $195.27 million (2022-12-31) to $139.80 million (2025-12-31), a change of -28.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1462418, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ALTISOURCE PORTFOLIO SOLUTIONS S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ALTISOURCE PORTFOLIO SOLUTIONS S.A. (CIK 1462418) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-23, and the most recent 10-K annual report was filed 2026-03-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 215 8-K or 6-K reports in ALTISOURCE PORTFOLIO SOLUTIONS S.A.’s recent EDGAR index, the 4 listed here run from 2026-03-04 to 2026-07-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1462418 is on the EDGAR company page; the latest 10-K there is dated 2026-03-04 and the oldest filing in the recent index dates from 2010-07-13. Insider trades for ALTISOURCE PORTFOLIO SOLUTIONS S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ameriserv financial, inc. bullish and bearish analyst opinions

This section ties “Ameriserv financial, inc. bullish and bearish analyst opinions” to AMERISERV FINANCIAL INC /PA/ (ticker ASRV), SEC Central Index Key 707605, an EDGAR registrant classified as “National Commercial Banks” and organised in PA, formerly known as USBANCORP INC /PA/. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-18 by AMERISERV FINANCIAL INC /PA/ (CIK 707605) — source document:

AmeriServ Financial, Inc. (the Company) is a bank holding company organized under the Pennsylvania Business Corporation Law. The Company became a holding company upon acquiring all of the outstanding shares of AmeriServ Financial Bank (the Bank) in January 1983. When used in this report, the “Company” may refer, depending on the context, to AmeriServ Financial, Inc. individually or AmeriServ Financial, Inc. and its direct subsidiary. The Company’s principal activities consist of owning and operating its wholly owned subsidiary entity. At December 31, 2025, the Company had, on a consolidated basis, total assets, deposits, and shareholders’ equity of $1.5 billion, $1.2 billion, and $119.3 million, respectively. The Company and its subsidiary derive substantially all of their income from banking, bank related services, and trust and wealth management related services.

Financial trend for AMERISERV FINANCIAL INC /PA/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $14.74 million (2022-12-31) to $14.63 million (2025-12-31), a change of -0.7%; net income (loss) went from $7.45 million (2022-12-31) to $5.61 million (2025-12-31), a change of -24.7%; total assets went from $1.36 billion (2022-12-31) to $1.45 billion (2025-12-31), a change of +6.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 707605, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures AMERISERV FINANCIAL INC /PA/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AMERISERV FINANCIAL INC /PA/ (CIK 707605) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-20, and the most recent 10-K annual report was filed 2026-03-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

For reported results, AMERISERV FINANCIAL INC /PA/’s (CIK 707605) latest 10-Q is dated 2026-08-14 and its latest annual report (10-K) 2026-03-18. Earnings releases appear as 8-K Item 2.02 filings; 59 are in the recent index, the newest on 2026-10-20.

Current reports. Of the 159 8-K or 6-K reports in AMERISERV FINANCIAL INC /PA/’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 707605 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2012-05-15. Insider trades for AMERISERV FINANCIAL INC /PA/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aptera motors corp. bullish and bearish analyst opinions

This section ties “Aptera motors corp. bullish and bearish analyst opinions” to Aptera Motors Corp (ticker SEV), SEC Central Index Key 1786471, an EDGAR registrant classified as “Motor Vehicles & Passenger Car Bodies” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-21. Nothing here is a recommendation to trade the security.

Financial trend for Aptera Motors Corp from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from -$34.91 million (2024-12-31) to -$43.91 million (2025-12-31), a change of -25.8%; total assets went from $34.93 million (2024-12-31) to $30.24 million (2025-12-31), a change of -13.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1786471, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Aptera Motors Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aptera Motors Corp (CIK 1786471) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 25 8-K or 6-K reports in Aptera Motors Corp’s recent EDGAR index, the 4 listed here run from 2026-08-20 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 222 recent EDGAR filings, Aptera Motors Corp most often filed 8-K (25), CORRESP (22), 4 (20), 253G2 (20). A selection from 2026-10-09 to 2026-10-16:

The full record for CIK 1786471 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2019-08-28. Insider trades for Aptera Motors Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Atea asa bullish and bearish analyst opinions

The legal-form ending in “Atea asa” is the clue: “ASA” is the Norwegian public limited company form (allmennaksjeselskap). A company of that kind reports in Norway, so the place to read its annual report and announcements is the Oslo Børs NewsWeb disclosure service — newsweb.oslobors.no.

No SEC filer could be matched to “Atea asa bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Atea asa” appears in 10000+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “atea” (search terms considered: atea).

The wording suggests a business based in Norway. Companies there file with Oslo Børs and Finanstilsynet rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “atea” is therefore the Norway regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Atea asa”, filings range from 2019-11-18 to 2026-10-23. The filers whose documents mention it most often are HARRIS ASSOCIATES INVESTMENT TRUST (CIK 0000872323) (27 hits); iSHARES TRUST (CIK 0001100663) (23 hits); Global X Funds (CIK 0001432353) (22 hits); AMG Funds IV (CIK 0000912036) (13 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 3 entities whose registered name contains the word “atea”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “atea” 3. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “atea” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Aurora optoelectronics co.,ltd. bullish and bearish analyst opinions

Read from its name, “Aurora optoelectronics co.,ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Aurora optoelectronics co.,ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Aurora optoelectronics co.,ltd.” appears in 45 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “aurora” (search terms considered: aurora, optoelectronics).

A broader EDGAR full-text search for the shorter phrase “Aurora optoelectronics co.” finds 45 filing documents; among the top 45, the filers mentioning it most are VANGUARD INTERNATIONAL EQUITY INDEX FUNDS (CIK 0000857489) (11); VanEck Vectors ETF Trust (CIK 0001137360) (10); iSHARES TRUST (CIK 0001100663) (9). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 45 most relevant full-text hits returned for “Aurora optoelectronics co.,ltd.”, filings range from 2016-06-23 to 2018-08-30. The filers whose documents mention it most often are VANGUARD INTERNATIONAL EQUITY INDEX FUNDS (CIK 0000857489) (11 hits); VanEck Vectors ETF Trust (CIK 0001137360) (10 hits); iSHARES TRUST (CIK 0001100663) (9 hits); CSOP ETF Trust (CIK 0001617113) (8 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 187+ entities whose registered name contains the word “aurora”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “aurora” 234, “optoelectronics” 10. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “aurora” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Avidbank holdings, inc. bullish and bearish analyst opinions

This section ties “Avidbank holdings, inc. bullish and bearish analyst opinions” to Avidbank Holdings, Inc. (ticker AVBH), SEC Central Index Key 1443575, an EDGAR registrant classified as “State Commercial Banks” and organised in CA, formerly known as PENINSULA BANK HOLDING CO. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-18 by Avidbank Holdings, Inc. (CIK 1443575) — source document:

We are Avidbank Holdings, a bank holding company based in San Jose, California that operates through our wholly owned subsidiary, Avidbank, a California state-chartered bank ("Avidbank" or the "Bank"). Founded in 2003, Avidbank is a full-service commercial bank dedicated to providing innovative banking solutions to a diverse client base, including small-to-medium sized businesses, technology companies, and individuals through robust portfolios of lending products, deposit services, and digital banking capabilities. We believe we provide competitive deposit products and treasury management solutions with a high-touch, relationship-driven approach, guided by our commitment to being Responsive, Collaborative & Accountable—principles we embody in every client interaction. Our experienced management team focuses on loan growth while striving to maintain excellent credit quality, core deposit expansion, noninterest income growth and improving operational efficiency.

Financial trend for Avidbank Holdings, Inc. from annual reports, periods 2024-12-31 to 2025-12-31: revenue went from $142.44 million (2024-12-31) to $145.75 million (2025-12-31), a change of +2.3%; net income (loss) went from $21.02 million (2024-12-31) to -$19.55 million (2025-12-31), a change of -193.0%; total assets went from $2.30 billion (2024-12-31) to $2.57 billion (2025-12-31), a change of +11.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1443575, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 2 periods shown, dashes mark figures Avidbank Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Avidbank Holdings, Inc. (CIK 1443575) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-23, and the most recent 10-K annual report was filed 2026-03-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 11 8-K or 6-K reports in Avidbank Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-21 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1443575 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2008-08-15. Insider trades for Avidbank Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bain capital gss investment cor bullish and bearish analyst opinions

This section ties “Bain capital gss investment cor bullish and bearish analyst opinions” to Bain Capital GSS Investment Corp. (ticker BCSS, BCSS-UN, BCSS-WT), SEC Central Index Key 2064355, an EDGAR registrant classified as “Blank Checks” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-20 by Bain Capital GSS Investment Corp. (CIK 2064355) — source document:

We are a newly organized blank check company incorporated on March 24, 2025 as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Annual Report as our “initial business combination” or our “business combination”. Our sponsor, Bain Capital GSS Investment Sponsor LLC, is a Delaware limited liability company that was formed for the sole purpose of holding securities in the U.S. and providing certain services pursuant to the administrative services and indemnification agreement, as further described herein. Our sponsor is controlled by our controlling members.

Financial trend for Bain Capital GSS Investment Corp. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from -$20,600 (2025-09-30) to $3.95 million (2026-06-30), a change of +19286.8%; total assets went from $9.61 million (2025-09-30) to $474.17 million (2026-06-30), a change of +4835.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2064355, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Bain Capital GSS Investment Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bain Capital GSS Investment Corp. (CIK 2064355) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 5 8-K or 6-K reports in Bain Capital GSS Investment Corp.’s recent EDGAR index, the 4 listed here run from 2025-10-07 to 2026-02-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2064355 is on the EDGAR company page; the latest 10-K there is dated 2026-03-20 and the oldest filing in the recent index dates from 2025-06-13. Insider trades for Bain Capital GSS Investment Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bayfirst financial corp. bullish and bearish analyst opinions

This section ties “Bayfirst financial corp. bullish and bearish analyst opinions” to BayFirst Financial Corp. (ticker BAFN), SEC Central Index Key 1649739, an EDGAR registrant classified as “State Commercial Banks” and organised in FL. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Financial trend for BayFirst Financial Corp. from annual reports, periods 2025-03-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at -$24.57 million; total assets went from $1.29 billion (2025-03-31) to $1.29 billion (2025-12-31), a change of +0.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1649739, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures BayFirst Financial Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BayFirst Financial Corp. (CIK 1649739) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

For reported results, BayFirst Financial Corp.’s (CIK 1649739) latest 10-Q is dated 2026-08-14 and its latest annual report (10-K) 2026-03-27. Earnings releases appear as 8-K Item 2.02 filings; 21 are in the recent index, the newest on 2026-08-13.

Current reports. Of the 105 8-K or 6-K reports in BayFirst Financial Corp.’s recent EDGAR index, the 4 listed here run from 2026-09-01 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 790 recent EDGAR filings, BayFirst Financial Corp. most often filed 4 (573), 8-K (105), 3 (26), 10-Q (15). A selection from 2026-10-13 to 2026-10-19:

The full record for CIK 1649739 is on the EDGAR company page; the latest 10-K/A there is dated 2026-08-12 and the oldest filing in the recent index dates from 2021-05-11. Insider trades for BayFirst Financial Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bowhead specialty holdings inc. bullish and bearish analyst opinions

This section ties “Bowhead specialty holdings inc. bullish and bearish analyst opinions” to Bowhead Specialty Holdings Inc. (ticker BOW), SEC Central Index Key 2002473, an EDGAR registrant classified as “Fire, Marine & Casualty Insurance” and organised in DE, formerly known as Bowhead Holdings Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SC 13E3/A dated 2026-10-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-24 by Bowhead Specialty Holdings Inc. (CIK 2002473) — source document:

Who We Are We were founded in September 2020, backed by capital provided by GPC Partners Investments (SPV III) LP (“GPC Fund”), a private equity fund managed by Gallatin Point Capital LLC (“Gallatin Point”), and our strategic partner, AmFam, to take advantage of favorable pricing environments, and to address a growing and unmet demand from brokers and policyholders for specialized insurance solutions and quality service in complex lines of business. Our principal objective is to create and sustain superior returns for our stockholders by generating consistent, underwriting profits across our product offerings and through all market cycles, while prudently managing capital. We offer commercial specialty property and casualty (“P&C”) insurance products to policyholders that vary in size, industry and complexity, focusing on casualty, professional liability, and healthcare liability risks.

Financial trend for Bowhead Specialty Holdings Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $187.60 million (2022-12-31) to $551.59 million (2025-12-31), a change of +194.0%; net income (loss) went from $11.26 million (2022-12-31) to $53.79 million (2025-12-31), a change of +377.8%; total assets went from $1.03 billion (2023-12-31) to $2.37 billion (2025-12-31), a change of +130.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2002473, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Bowhead Specialty Holdings Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bowhead Specialty Holdings Inc. (CIK 2002473) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-03, and the most recent 10-K annual report was filed 2026-02-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 21 8-K or 6-K reports in Bowhead Specialty Holdings Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2002473 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2023-12-21. Insider trades for Bowhead Specialty Holdings Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Briacell therapeutics corp. bullish and bearish analyst opinions

This section ties “Briacell therapeutics corp. bullish and bearish analyst opinions” to BriaCell Therapeutics Corp. (ticker BCTX, BCTXL, BCTXZ), SEC Central Index Key 1610820, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in British Columbia, Canada, formerly known as Ansell Capital Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-06-26. Nothing here is a recommendation to trade the security.

Financial trend for BriaCell Therapeutics Corp. from annual reports, periods 2022-07-31 to 2025-07-31: net income (loss) went from -$26.84 million (2022-07-31) to -$26.31 million (2025-07-31), a change of +2.0%; total assets went from $42.58 million (2022-07-31) to $21.65 million (2025-07-31), a change of -49.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1610820, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures BriaCell Therapeutics Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BriaCell Therapeutics Corp. (CIK 1610820) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2022-10-28, and the most recent 10-K annual report was filed 2025-10-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 116 8-K or 6-K reports in BriaCell Therapeutics Corp.’s recent EDGAR index, the 4 listed here run from 2026-03-09 to 2026-06-26, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 323 recent EDGAR filings, BriaCell Therapeutics Corp. most often filed 8-K (65), 6-K (51), CORRESP (32), F-1/A (15). A selection from 2026-02-12 to 2026-06-09:

The full record for CIK 1610820 is on the EDGAR company page; the latest 10-K there is dated 2025-10-16 and the oldest filing in the recent index dates from 2014-06-20. Insider trades for BriaCell Therapeutics Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

C3is inc. bullish and bearish analyst opinions

This section ties “C3is inc. bullish and bearish analyst opinions” to C3is Inc. (ticker CISS), SEC Central Index Key 1951067, an EDGAR registrant classified as “Deep Sea Foreign Transportation of Freight” and organised in Marshall Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-10-16. Nothing here is a recommendation to trade the security.

Financial trend for C3is Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $28.74 million (2023-12-31) to $34.76 million (2025-12-31), a change of +20.9%; net income (loss) went from $9.29 million (2023-12-31) to $10.47 million (2025-12-31), a change of +12.7%; total assets went from $39.86 million (2022-12-31) to $98.49 million (2025-12-31), a change of +147.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1951067, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures C3is Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on C3is Inc. (CIK 1951067) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 50 8-K or 6-K reports in C3is Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-17 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 316 recent EDGAR filings, C3is Inc. most often filed 424B3 (94), 6-K (50), EFFECT (27), POS AM (22). A selection from 2026-10-05 to 2026-10-16:

The full record for CIK 1951067 is on the EDGAR company page; the latest 20-F there is dated 2026-04-22 and the oldest filing in the recent index dates from 2022-12-07. Insider trades for C3is Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cib marine bancshares, inc. bullish and bearish analyst opinions

This section ties “Cib marine bancshares, inc. bullish and bearish analyst opinions” to CIB MARINE BANCSHARES INC (ticker none listed), SEC Central Index Key 861955, an EDGAR registrant classified as “State Commercial Banks” and organised in WI, formerly known as CENTRAL ILLINOIS BANCORP INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2012-08-10. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2012-03-23 by CIB MARINE BANCSHARES INC (CIK 861955) — source document:

CIB MARINE CIB Marine Bancshares, Inc. (“CIB Marine”) is a one-bank holding company with its principal executive offices in Waukesha, Wisconsin, a suburb of Milwaukee. CIB Marine is a corporation formed under the laws of the State of Wisconsin in 1999. At December 31, 2011, CIB Marine owned and operated CIBM Bank, a commercial banking organization with offices in Illinois, Wisconsin and Indiana. CIBM Bank offers a full array of traditional banking services. These services include a broad range of loan products, such as commercial loans, commercial real estate loans, construction and development loans, residential real estate loans, consumer loans, and commercial and standby letters of credit; accepting demand, savings and time deposits, providing commercial paper and repurchase agreements; and providing other banking services.

Financial trend for CIB MARINE BANCSHARES INC from annual reports, periods 2009-12-31 to 2011-12-31: revenue went from $39.41 million (2009-12-31) to $25.69 million (2011-12-31), a change of -34.8%; net income (loss) went from $13.72 million (2009-12-31) to -$5.42 million (2011-12-31), a change of -139.5%; total assets went from $589.03 million (2010-12-31) to $503.98 million (2011-12-31), a change of -14.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 861955, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 3 periods shown, dashes mark figures CIB MARINE BANCSHARES INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CIB MARINE BANCSHARES INC (CIK 861955) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2012-03-23, and the most recent 10-K annual report was filed 2012-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 109 8-K or 6-K reports in CIB MARINE BANCSHARES INC’s recent EDGAR index, the 4 listed here run from 2012-05-11 to 2012-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 861955 is on the EDGAR company page; the latest 10-K there is dated 2012-03-23 and the oldest filing in the recent index dates from 1998-04-30. Insider trades for CIB MARINE BANCSHARES INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Codere online luxembourg, s.a. bullish and bearish analyst opinions

This section ties “Codere online luxembourg, s.a. bullish and bearish analyst opinions” to Codere Online Luxembourg, S.A. (ticker CDRO, CDROW), SEC Central Index Key 1866782, an EDGAR registrant classified as “Services-Miscellaneous Amusement & Recreation” and organised in Luxembourg. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-30. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-28 by Codere Online Luxembourg, S.A. (CIK 1866782) — source document:

Codere Online Luxembourg, S.A. was incorporated under the laws of the Grand Duchy of Luxembourg by Codere Newco on June 4, 2021 as a limited liability company ( société anonyme ) having its registered office at 7 rue Robert Stümper, L-2557 Luxembourg, Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies Register ( Registre de Commerce et des Sociétés, Luxembourg ) under number B255798 and with telephone number +34 91354 28 19. Codere Online Luxembourg, S.A. was incorporated with an initial share capital of €30,000, represented by 30,000 Ordinary Shares with a nominal value of €1 per share. The Ordinary Shares and Codere Online Warrants began trading on the Nasdaq Capital Market on December 1, 2021, under the symbols “CDRO” and “CDROW,” respectively.

Financial trend for Codere Online Luxembourg, S.A. from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 80,253,000 EUR (2021-12-31) to 200,704,000 EUR (2024-12-31), a change of +150.1%; net income (loss) went from -68,013,000 EUR (2021-12-31) to 3,910,000 EUR (2024-12-31), a change of +105.7%; total assets went from 105,275,000 EUR (2021-12-31) to 74,540,000 EUR (2024-12-31), a change of -29.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1866782, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Codere Online Luxembourg, S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Codere Online Luxembourg, S.A. (CIK 1866782) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 89 8-K or 6-K reports in Codere Online Luxembourg, S.A.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1866782 is on the EDGAR company page; the latest 20-F there is dated 2026-04-28 and the oldest filing in the recent index dates from 2021-06-22. Insider trades for Codere Online Luxembourg, S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Coherus oncology, inc. bullish and bearish analyst opinions

This section ties “Coherus oncology, inc. bullish and bearish analyst opinions” to Coherus Oncology, Inc. (ticker CHRS), SEC Central Index Key 1512762, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE, formerly known as Coherus BioSciences, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-28. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-09 by Coherus Oncology, Inc. (CIK 1512762) — source document:

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.

Financial trend for Coherus Oncology, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$291.75 million (2022-12-31) to $168.02 million (2025-12-31), a change of +157.6%; total assets went from $480.85 million (2022-12-31) to $258.34 million (2025-12-31), a change of -46.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1512762, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Coherus Oncology, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Coherus Oncology, Inc. (CIK 1512762) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 196 8-K or 6-K reports in Coherus Oncology, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-08-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1512762 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2011-02-23. Insider trades for Coherus Oncology, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cytosorbents corporation bullish and bearish analyst opinions

This section ties “Cytosorbents corporation bullish and bearish analyst opinions” to Cytosorbents Corp (ticker CTSO), SEC Central Index Key 1175151, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE, formerly known as MedaSorb Technologies CORP. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Cytosorbents Corp (CIK 1175151) — source document:

We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications.

Financial trend for Cytosorbents Corp from annual reports, periods 2024-06-30 to 2025-12-31: net income (loss) went from -$20.72 million (2024-12-31) to -$8.20 million (2025-12-31), a change of +60.4%; total assets went from $53.43 million (2024-06-30) to $44.18 million (2025-12-31), a change of -17.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1175151, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Cytosorbents Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cytosorbents Corp (CIK 1175151) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 285 8-K or 6-K reports in Cytosorbents Corp’s recent EDGAR index, the 4 listed here run from 2026-08-07 to 2026-09-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1175151 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-15 and the oldest filing in the recent index dates from 2004-03-29. Insider trades for Cytosorbents Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET